

February 13, 2009

To whom it may concern:

5-2-1 Daizawa, Setagaya Ward, Tokyo
Toho Pharmaceutical Co., Ltd.
(Tokyo Stock Exchange Securities Code: 8129)
Norio Hamada, President and CEO
contact:
Mamoru Ogino
Executive Corporate Officer,
Joint General Manager of Administration Division
(TEL: 03-4330-3735)

Notice of Acquisition of Company Stock
(Acquisition of Company Stock Pursuant to Articles of Incorporation
under Article 165, Paragraph 2 of Corporations Law)

Toho Pharmaceutical Co., Ltd. (the Company) hereby announces that the Company's Board of Directors, at its meeting held on February 13, 2009, resolved the Company's acquisition of stock in the Company, pursuant to Article 156 of the Corporations Law, as applied mutatis mutandis under Article 165, Paragraph 3 of the Law.

1. Reason of Acquisition of Company Stock

To make it possible to carry out a flexible capital policy.

2. Acquisition Details

- (1) Type of stock acquired: Common stock of this company
- (2) Total number of shares acquired: 2,000,000 (Limit)
- (3) Total cost of stock acquired: 2,500,000,000 yen (Limit)
- (4) Period of acquisition: from February 16, 2009 to March 24, 2009

(For Reference)

Company Stock Held by the Company in Treasury as of January 31, 2009

- Number of shares issued and outstanding (excluding common stock for treasury): 60,728,947 share
- Number of shares held in treasury: 37,675 share